Functional Response to Cholinesterase Inhibitor Therapy in a Naturalistic Alzheimer's Disease Cohort
Background Activities of daily living (ADL) are an essential part of the diagnostic criteria for Alzheimer's disease (AD ... Functional response to cholinesterase inhibitor (ChEI) treatment ...
Viral Chatter on MSN9d
Scientists Link Early Neuron Loss to Alzheimer’s TreatmentsA landmark study examining over 3.4 million brain cells has revealed that Alzheimer’s disease progresses through two distinct ...
The Brighterside of News on MSN10d
Breakthrough Alzheimer’s drug slows down cognitive decline in dementia patientsLewy body disease (LBD), which includes dementia with Lewy bodies (DLB) and Parkinson’s disease with or without dementia, is ...
Dementia is a condition that affects memory, thinking, and the ability to perform everyday tasks. As it progresses, it can ...
Who Should be Started on a Cholinesterase Inhibitor? A ChEI is an option for most people with mild to moderate AD (the commonly seen behavioural signs of this phase of AD are shown in Table 1).
When a person has Alzheimer’s disease or dementia with Lewy bodies, they have less acetylcholine. This means that their nerve cells lose the ability to talk to each other properly. Cholinesterase ...
Amyloid-β (Aβ)-rich plaques and tau-containing neurofibrillary tangles are neuropathological hallmarks of Alzheimer's disease (AD). Currently approved drugs for AD target cholinesterase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback